Compare Amylx Pharmaceuticals Inc (AMLX) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs PPG Industries, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while PPG Industries, Inc. trades at $116.76 (market cap $26.03B). The key difference: PPG Industries, Inc. is far larger — about 13.1× Amylx Pharmaceuticals Inc's market cap, and PPG Industries, Inc. pays a 2.43% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PPG | |
|---|---|---|
Market Cap | $1.98B | $26.03B |
Sector | Health | Basic Materials |
52-Week High | $18.70 | $131.56 |
52-Week Low | $7.64 | $94.34 |
Enterprise Value | $1.70B | $32.13B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
PPG Industries trades at $116.76, up 0.69% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 9.83% net margin and 21.09% ROE, supported by $15.88B in 2025 revenue. Analysts show a 52.63% buy consensus with a $131.75 price target. Recent news highlights innovation in aerospace and marine coatings, though sentiment remains mixed amid modest revenue growth.
PPG offers solid fundamentals and dividend stability but faces headwinds from volume softness and margin pressure. The stock's valuation at a P/E of 16.73 appears reasonable, yet near-term catalysts are limited. Risks include economic sensitivity and competitive pressures, while institutional support and consistent cash flow provide a floor. The outlook is neutral with upside dependent on execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
